Burcon Rights to Commence Trading on February 14, 2014

Burcon Rights to Commence Trading on February 14, 2014

VANCOUVER, British Columbia, Feb. 7, 2014 (GLOBE NEWSWIRE) -- Burcon
NutraScience Corporation (TSX:BU) (Nasdaq:BUR) ("Burcon") announced earlier
today that it will be offering rights (the "Rights") to holders of its common
shares of record at the close of business on February 19, 2014. Please be
advised that the Rights will commence trading on the Toronto Stock Exchange
("TSX") on February 14, 2014 and not February 17, 2014 as previously

This press release does not constitute an offer to sell or the solicitation of
an offer to buy any of the securities described herein. Such securities may
not be offered or sold in the United States absent registration under the
United States Securities Act of 1933, as amended (the "U.S. Securities Act")
and applicable state securities laws, or absent an available exemption from
such registration requirements. Any securities sold pursuant to the Standby
Commitment Agreement have not and will not be registered under the U.S.
Securities Act.

About Burcon NutraScience Corporation

Burcon is a leader developing functionally superior plant-based proteins.
Burcon has developed a portfolio of composition, application, and process
patents originating from a core protein extraction and purification
technology. Burcon's CLARISOY™ soy protein offers clarity and high-quality
protein nutrition for low pH beverage systems; Peazazz® is a uniquely soluble
and clean-tasting pea protein; and Puratein®, Supertein™ and Nutratein® are
canola protein isolates with unique functional and nutritional attributes. For
more information about Burcon, visit www.burcon.ca.


"Johann F. Tergesen"
Johann F. Tergesen
President and Chief Operating Officer

The TSX has not reviewed and does not accept responsibility for the adequacy
of the content of the information contained herein. This press release
contains forward-looking statements or forward-looking information.
Forward-looking statements or forward-looking information involve risks,
uncertainties and other factors that could cause actual results, performances,
prospects and opportunities to differ materially from those expressed or
implied by such forward-looking statements. All statements other than
statements of historical fact included in this press release are
forward-looking statements, including, without limitation, statements with
respect to Burcon's intention to complete the rights offering and the timing
and procedures related thereto, and the listing of the Rights on the TSX and
the timing thereof. There can be no assurance that such statements will prove
to be accurate and actual results and future events could differ materially
from those anticipated in such statements or information. Important factors
that could cause actual results to differ materially from Burcon's plans and
expectations include the actual results of marketing activities, adverse
general economic, market or business conditions, regulatory changes and other
risks and factors detailed from time to time in the filings made by Burcon
with securities regulators and stock exchanges, including in the section
entitled "Risk Factors" in Burcon's annual information form dated June 25,
2013. Any forward-looking statement or information only speaks as of the date
on which it was made and, except as may be required by applicable securities
laws, Burcon disclaims any intent or obligation to update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Although Burcon believes that the assumptions inherent in the forward-looking
statements are reasonable, forward-looking statements are not guarantees of
future performance. Accordingly, undue reliance should not be put on such
forward-looking statements.

CLARISOY is a trademark of Archer Daniels Midland Company.

CONTACT: Media & Industry Contact:
         Michael Kirwan
         Director, Corporate Development
         Burcon NutraScience Corporation
         Tel (604) 733-0896, Toll-free (888) 408-7960
         Investor Relations Contact:
         Matt Glover or Michael Koehler
         Liolios Group Inc.
         Tel (949) 574-3860
Press spacebar to pause and continue. Press esc to stop.